Healthcare Industry News: HSMN NewsFeed
News Release - May 29, 2018
ADAPT Pharma(R) Launches NARCANDirect.comNew online platform for Group Purchasers of NARCANŽ (naloxone HCl) Nasal Spray
DUBLIN, May 29, 2018 -- (Healthcare Sales & Marketing Network) -- ADAPT PharmaŽ (Adapt) announced the launch of NARCANDirect.com, an easy-to-use online platform for qualifying group purchasers of NARCANŽ Nasal Spray (NARCAN). NARCANDirect.com was created to facilitate:
- Direct purchase of NARCANŽ (naloxone HCl) Nasal Spray from Adapt at a 40% discount of $37.50/dose ($75 per 2 dose carton)
- Central ordering and billing, with local delivery to multiple designated qualifying recipients; and
- Rapid online ordering, shipment tracking, as well as product expiration and other information.
"ADAPT PharmaŽ has helped us develop and operationalize our state-wide distribution network for NARCANŽ Nasal Spray. Adapt's process has helped us set up multiple distribution points enabling the management of a single bill while distributing across the state to first responders and our Single County Authorities (SCAs)," said Derin Myers, Acting Executive Director of the Pennsylvania Commission on Crime and Delinquency. "The NARCANDirect.com platform has the capability to make managing state-wide naloxone distribution more efficient."
"NARCANDirect.com was developed to support group purchasers of NARCANŽ tasked with accessing and rapidly distributing NARCANŽ to those first responders on the frontlines of this opioid epidemic," said Matt Ruth, US Chief Commercial Officer, Adapt.
Existing customer details will be pre-loaded onto NARCANDirect.com. New customers are invited to complete the registration process to seek approval. NARCANDirect.com is subject to terms and conditions including a minimum order of one case of NARCANŽ (12 units). This online application complements the Adapt Customer Service line that continues to accept orders at 1-844-4-NARCAN or via email at email@example.com.
NARCANŽ Nasal Spray 4mg and the opioid overdose epidemic
In 2016, there were more than 42,000 deaths due to an opioid overdose, a 27 percent increase from 2015, making it the highest death rate on record.1
NARCANŽ Nasal Spray 4mg is the first and only FDA-approved, needle-free formulation of naloxone for the emergency treatment of a known or suspected opioid overdose. It does not require assembly or any specialized medical training and is also the highest concentrated dose of intranasal naloxone currently available. NARCANŽ Nasal Spray is not a substitute for emergency medical care, and additional doses of NARCANŽ Nasal Spray may be required until emergency medical assistance arrives. Seek emergency medical assistance immediately after initial use, keeping the patient under continued surveillance.
Please see Indications and Important Safety Information below.
NARCANŽ (naloxone hydrochloride) Nasal Spray is an opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression. NARCANŽ Nasal Spray is intended for immediate administration as emergency therapy in settings where opioids may be present. NARCANŽ Nasal Spray is not a substitute for emergency medical care.
Important Safety Information
NARCANŽ (naloxone HCI) Nasal Spray is contraindicated in patients known to be hypersensitive to naloxone hydrochloride or to any of the other ingredients.
Seek emergency medical assistance immediately after initial use, keeping the patient under continued surveillance.
Risk of Recurrent Respiratory and CNS Depression: Due to the duration of action of naloxone relative to the opioid, keep the patient under continued surveillance and administer repeat doses of naloxone using a new nasal spray with each dose, as necessary, while awaiting emergency medical assistance.
Risk of Limited Efficacy with Partial Agonists or Mixed Agonists/Antagonists: Reversal of respiratory depression caused by partial agonists or mixed agonists/antagonists, such as buprenorphine and pentazocine, may be incomplete. Larger or repeat doses may be required.
Precipitation of Severe Opioid Withdrawal: Use in patients who are opioid dependent may precipitate opioid withdrawal characterized by body aches, fever, sweating, runny nose, sneezing, piloerection, yawning, weakness, shivering or trembling, nervousness, restlessness or irritability, diarrhea, nausea or vomiting, abdominal cramps, increased blood pressure, and tachycardia. In some patients, there may be aggressive behavior upon abrupt reversal of an opioid overdose. In neonates, opioid withdrawal may be life-threatening if not recognized and properly treated and may also include convulsions, excessive crying, and hyperactive reflexes. Monitor for the development of opioid withdrawal.
Risk of Cardiovascular (CV) Effects: Abrupt postoperative reversal of opioid depression may result in adverse CV effects. These events have primarily occurred in patients who had pre-existing CV disorders or received other drugs that may have similar adverse CV effects. Monitor these patients closely in an appropriate healthcare setting after use of naloxone hydrochloride.
Adverse Reactions: The following adverse reactions were observed in a NARCANŽ Nasal Spray clinical study: increased blood pressure, constipation, toothache, muscle spasms, musculoskeletal pain, headache, nasal dryness, nasal edema, nasal congestion, nasal inflammation, rhinalgia, and xeroderma.
To report SUSPECTED ADVERSE REACTIONS, contact ADAPT Pharma, Inc. at 1-844-4-NARCAN (1-844-462-7226) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Please see full Prescribing Information at: https://www.narcan.com/pdf/NARCAN-Prescribing-Information.pdf.
For additional information on NARCANŽ Nasal Spray, please visit www.NARCAN.com.
For questions regarding NARCANŽ Nasal Spray distribution, please call 1-844-4-NARCAN (462-7226).
ABOUT ADAPT PHARMAŽ
ADAPT PharmaŽ is a privately-held company committed to expanding affordable access to NarcanŽ (naloxone HCI) Nasal Spray and to progressing treatment options in the field of addiction. ADAPT Pharma's company headquarters is in Dublin, Ireland with U.S. headquarters in Radnor, Pennsylvania. For more information, please visit www.adaptpharma.com.
1 Opioid Overdose. Centers for Disease Control and Prevention. https://www.cdc.gov/drugoverdose/index.html. Last accessed March 20, 2018.
Source: ADAPT Pharma
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.